Predicting prostate cancer many years before diagnosis: how and why?

Area of Science:

• Urology
• Oncology
• Preventive Medicine

Background:

• Prostate-specific antigen (PSA) screening is linked to reduced prostate cancer mortality in European trials.
• Significant controversy exists regarding PSA screening due to concerns about overdiagnosis and overtreatment, questioning if benefits outweigh risks.
• Current risk stratification methods like family history and genomic markers are insufficient for practical application.

Purpose of the Study:

• To evaluate the prognostic value of PSA levels for long-term aggressive prostate cancer risk.
• To propose a risk-stratified approach for PSA screening to optimize the benefit-to-harm ratio.
• To identify high-risk populations who may benefit most from intensive monitoring.

Main Methods:

• Analysis of evidence linking blood PSA levels to the long-term risk of aggressive prostate cancer.
• Review of randomized trials and epidemiological data on PSA screening outcomes.
• Development of age- and PSA-level-based screening interval recommendations.

Main Results:

• PSA levels are strongly prognostic for aggressive prostate cancer risk.
• Screening men aged 60+ with PSA <1-2 ng/ml may not be justifiable.
• Tailored screening intervals based on PSA levels (e.g., 1-2 years for PSA ≥1 ng/ml in men 45-60, 6-8 years for PSA <1 ng/ml).
• Men with top 10% PSA levels (≥1.5 ng/ml under 50) are at high risk and require intensive monitoring.

Conclusions:

• PSA levels offer valuable prognostic information for prostate cancer risk stratification.
• Personalized screening strategies based on PSA levels can enhance the effectiveness of early detection.
• Targeting high-risk individuals with intensive monitoring can improve outcomes and mitigate screening harms.